Evidence map›Paper›PMID 34034754›Full record

ArticleMalaria journal2021

Therapeutic efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015-2016.

Youssouf Diarra, Oumar Koné, Lansana Sangaré, Lassina Doumbia, Dade Bouye Ben Haidara, Mouctar Diallo, Ababacar Maiga, Hamadoun A Sango, Halidou Sidibé, Jules Mihigo and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Youssouf DiarraUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Oumar KonéUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Lansana SangaréUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Lassina DoumbiaUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Dade Bouye Ben HaidaraReferral Health Centre of Sélingué, Ministry of Health and Public Hygiene, Bamako, Mali.
Mouctar DialloUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Ababacar MaigaUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Hamadoun A SangoUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Halidou SidibéNational Malaria Control Programme, Ministry of Health and Public Hygiene, Bamako, Mali.
Jules MihigoU.S. President's Malaria Initiative, USAID Office, Bamako, Mali.
Douglas NaceMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Dragan LjoljeMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Eldin TalundzicMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Venkatachalam UdhayakumarMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Erin EckertRTI International, Washington, DC, USA.
Celia J WoodfillU.S. President's Malaria Initiative, USAID Office, Bamako, Mali.
Leah F MoriartyMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Pharath LimMedical Care Development International, Silver Spring, MD, USA.
Donald J KrogstadTulane School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Eric S HalseyMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Naomi W LucchiMalaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ousmane A KoitaUniversity of Sciences, Techniques and Technologies of Bamako, Bamako, Mali. okoita@icermali.org.ORCID http://orcid.org/0000-0001-6535-3323

Funding

Sequencing and Genomics CoresU19AI089696 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KROGSTAD, DONALD JOHN · 2010 to 2016
$10.6M
NIAID NIH HHS U19 AI089696
6 · The paper itself

Abstract

backgroundThe current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). From 2015 to 2016, an in vivo study was carried out to assess the clinical and parasitological responses to AL and ASAQ in Sélingué, Mali.

methodsChildren between 6 and 59 months of age with uncomplicated Plasmodium falciparum infection and 2000-200,000 asexual parasites/μL of blood were enrolled, randomly assigned to either AL or ASAQ, and followed up for 42 days. Uncorrected and PCR-corrected efficacy results at days 28 and 42. were calculated. Known markers of resistance in the Pfk13, Pfmdr1, and Pfcrt genes were assessed using Sanger sequencing.

resultsA total of 449 patients were enrolled: 225 in the AL group and 224 in the ASAQ group. Uncorrected efficacy at day 28 was 83.4% (95% CI 78.5-88.4%) in the AL arm and 93.1% (95% CI 89.7-96.5%) in the ASAQ arm. The per protocol PCR-corrected efficacy at day 28 was 91.0% (86.0-95.9%) in the AL arm and 97.1% (93.6-100%) in the ASAQ arm. ASAQ was significantly (p < 0.05) better than AL for each of the aforementioned efficacy outcomes. No mutations associated with artemisinin resistance were identified in the Pfk13 gene. Overall, for Pfmdr1, the N86 allele and the NFD haplotype were the most common. The NFD haplotype was significantly more prevalent in the post-treatment than in the pre-treatment isolates in the AL arm (p < 0.01) but not in the ASAQ arm. For Pfcrt, the CVIET haplotype was the most common.

conclusionsThe findings indicate that both AL and ASAQ remain effective for the treatment of uncomplicated malaria in Sélingué, Mali.

Indexed as

AmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChild, PreschoolDrug CombinationsFemaleHumansInfantMalaria, FalciparumMaleMaliAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsAntimalarial resistanceArtemether–lumefantrineArtesunate–amodiaquineEfficacyMalariaMaliPfcrtPfk13Pfmdr1

Identifiers

PMID34034754
PMCPMC8146210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.